Canada - français - Health Canada

bristol-myers squibb canada - pomalidomide - capsule - 2mg - pomalidomide 2mg - antineoplastic agents

Canada - français - Health Canada

bristol-myers squibb canada - pomalidomide - capsule - 3mg - pomalidomide 3mg - antineoplastic agents

Canada - français - Health Canada

bristol-myers squibb canada - pomalidomide - capsule - 4mg - pomalidomide 4mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - le myélome multiple - agents antinéoplasiques - empliciti est indiqué en association avec le lénalidomide et la dexaméthasone pour le traitement du myélome multiple chez les patients adultes qui ont reçu au moins un traitement antérieur (voir les sections 4. 2 et 5.

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - isatuximab - le myélome multiple - agents antinéoplasiques - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.

Union européenne - français - EMA (European Medicines Agency)

theravia - dexaméthasone - le myélome multiple - corticostéroïdes à usage systémique - traitement du myélome multiple.

Canada - français - Health Canada

sanofi-aventis canada inc - isatuximab - solution - 100mg - isatuximab 100mg - antineoplastic agents

Canada - français - Health Canada

sanofi-aventis canada inc - isatuximab - solution - 500mg - isatuximab 500mg - antineoplastic agents

Canada - français - Health Canada

janssen inc - daratumumab - solution - 1800mg - daratumumab 1800mg - antineoplastic agents

Union européenne - français - EMA (European Medicines Agency)

oncopeptides ab - melphalan flufenamide hydrochloride - le myélome multiple - agents antinéoplasiques - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.